GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
Needham & Company Reiterates Buy on GenMark Diagnostics (GNMK) Following 4Q
March 1, 2017 7:34 AM ESTNeedham & Company reiterated a Buy rating and $15.00 price target on GenMark Diagnostics (NASDAQ: GNMK) following the company's 4Q earnings report. GNMK's 4Q16 revenue was $14.9M. And its GAAP EPS was ($0.27) vs. consensus of ($0.27).
Analyst Mike Matson commented, "GNMK's 4Q16 revenue was consistent with... More
